INVESTIGATION & DESIGN


Renishaw´s engineering innovations open up hope for a cure for Parkinson

13/03/2020

CATEGORY: New advances BRAND: Renishaw



Renishaw, an international engineering company, has created a device used in an innovative clinical trial. Manufactured by Renishaw for the North Bristol NHS Trust Foundation, the device controls the exact dosage of a potential new drug, Glial Cell Line Derived Neurotrophic Factor (GDNF), which attempts to regenerate the loss of brain cells from dopamine in patients with Parkinson's and, therefore, improve your symptoms


The trial's conclusions are presented in a two-episode documentary on BBC-2, The Parkinson's Drug Trial: A Miracle Cure? Parkinson's Drug Trial: A Miracle Cure?

 

In collaboration with neurosurgeon specialist Professor Steven Gill, Renishaw has manufactured the dosing system for the new drug, which provides a practical method of overcoming the blood-brain barrier. To perform the test, the additively manufactured titanium device for dosing GDNF via micro-catheters was implanted into the skull of 42 patients into the putamen, a critical region of the brain for motor function. The device was implanted using Renishaw's neuromate surgical robot, which places four catheters in the brain.

 

The trial is funded by Parkinson’s UK, in collaboration with the Cure Parkinson’s Trust and in association with the North Bristol NHS Trust. The results presented on February 27 showed that the drug's dosing system performed its function accurately, and another similar Renishaw device called the 'neuroinfuse' is now being used in other clinical trials.

 

"This trial demonstrates that it is possible to repeatedly inoculate the drug safely, directly into the patient's brain, for months or years, through a small implanted device that protrudes above the skin behind the ear," explains Professor Steven. Gill. "This represents a significant advance in our ability to treat neurological diseases, such as Parkinson's, since most potentially effective treatments cannot pass blood flow to the brain due to a natural protective barrier. Even in low doses, he sees an improvement in the patient, an enormously encouraging fact, ”adds Professor Gill. “Now, we have to continue to move towards a definitive clinical trial with higher doses, for which urgent funding is needed. I think this project could be the first neuro-reconstructive treatment for people with Parkinson's and, of course, it presents an exciting expectation. ”

 

 

“It has been a privilege to collaborate with the study team and the participants in this ambitious trial,” explains Paul Skinner, Renishaw CEO, Neurological Products. "We are highly motivated by the changes observed in brain scans, as they demonstrate that GDNF has effects and that the dosing system has accurately delivered the drug to the brain. This demonstrates the great potential of the drug dosing system, developed by Renishaw, for future studies on Parkinson's and experimental treatments for other neurodegenerative diseases and brain tumors. "

 

Más información www.renishaw.es

 

Return to the list

ADVERTISING